Atossa Therapeutics is a biopharmaceutical company focused on developing medicines for oncology and infectious diseases. Their lead program, Endoxifen, is in Phase II clinical trials for breast cancer treatment and prevention. Additionally, they are developing inhalation therapy and drug candidates for COVID-19 patients, along with immunotherapy for breast cancer treatment.